@FormalyTwilter Avatar @FormalyTwilter 佐藤雄二

佐藤雄二 posts on X about $aspi, $vnda, $nktr, $qure the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 54.31% finance 15.52% cryptocurrencies 8.62% countries 5.17% technology brands 4.31% financial services 3.45% social networks 0.86% exchanges 0.86% currencies 0.86%

Social topic influence $aspi 13.79%, $vnda 6.9%, $nktr #68, $qure #23, $eton 6.03%, eton 6.03%, stocks 5.17%, $xbi 4.31%, in the 4.31%, $crvs #32

Top accounts mentioned or mentioned by @mmatters22596 @9investobey @stocknear @aleabitoreddit @biotechautist @asamimes @brianskorney @leerinkpartners @clearstreetnews @takayamajoe @denebulord @tradingespada @nibingbingjie @xg3st57w994pqc @miuet496 @zethedeuce

Top assets mentioned ASP Isotopes Inc. (ASPI) uniQure N.V. (QURE) Tyra Biosciences, Inc. (TYRA) Kymera Therapeutics, Inc. (KYMR) Goldman Sachs (GS) Huma Finance (HUMA) Duolingo, Inc. (DUOL) Apogee Therapeutics, Inc. (APGE) Vertex Protocol (VRTX) Ocular Therapeutix, Inc. (OCUL) Skyline Builders Group Holding Limited (SKBL) Agios Pharmaceuticals, Inc. (AGIO) Eli Lilly and Company (LLY) Amgen, Inc. (AMGN) Merck & Co., Inc. (MRK) Biofrontera Inc. (BFRI) Aardvark Therapeutics, Inc (AARD) Evommune, Inc. (EVMN) Origin Protocol (OGN) Nuvation Bio Inc. (NUVB) Bitcoin (BTC) Novo-Nordisk (NVO) Alto Neuroscience, Inc. (ANRO) ALX Oncology Holdings Inc (ALXO) Sarepta Therapeutics, Inc. (SRPT) Wave Life Sciences Ltd. Ordinary Shares (WVE) United Airlines Holdings, Inc. (UAL) Tyler Technologies, Inc. (TYL) GammaSwap (GS) Reddit, Inc. (RDDT) Axsome Therapeutics, Inc (AXSM)

Top Social Posts

Top posts by engagements in the last [--] hours

"# # # Consolidated financial results for the fiscal year ending December Otsuka Holdings' net profit increases [---] times. Net profit and sales both reach record highs with pharmaceuticals performing well. #OtsukaPharmaceutical #Otsuka $ESPR # # # HD28 [--] https://t.co/1piRenXK3r # # # HD28 [--] https://t.co/1piRenXK3r"
X Link 2025-08-31T17:54Z [---] followers, [---] engagements

"$ANRO #ALTO-101 ALTO-101 PDE4 PDE4 cAMP ( )"
X Link 2026-01-19T20:44Z [---] followers, [---] engagements

"$ASPI $QLE $SKBL ( ) TerraPower $ASPI $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand."
X Link 2026-01-30T13:54Z [---] followers, [---] engagements

"$SKBL $SKBL [--] Panamax 220DOE DOE LPO60-70% IP $ASPI #SKBL #Uranium Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI"
X Link 2026-02-02T10:36Z [---] followers, [----] engagements

"$AGIO 400060% [----] [--] @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here. @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here"
X Link 2026-02-04T16:32Z [---] followers, [---] engagements

"$AGIO AgiosPharmaceuticals FDA AQVESME AQVESME [-------] $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year. $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year"
X Link 2026-02-04T16:36Z [---] followers, [---] engagements

"$NKTR $QURE ( ) Catalist Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before my https://t.co/1tBX30s0Ae Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before"
X Link 2026-02-04T20:40Z [---] followers, [----] engagements

"$LLY ( EliLilly )2026 Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR"
X Link 2026-02-04T20:51Z [---] followers, [--] engagements

"#FDA $AMGN #Amgen FDA Phase3 Amgen Tavneos - - FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z"
X Link 2026-02-04T21:39Z [---] followers, [---] engagements

"$TYRA #OPPENHEIMER MatthewBiegler $TYRA AnaChart [------] 3#Pricetarget $36$50 $4.98 (16.05%) $18.98 (61.19%) Outperform #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an increase in potential upside change from $4.98(16.05%) to $18.98(61.19%) with a rating of Outperform https://t.co/W9u958dQnd #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an"
X Link 2026-02-05T08:30Z [---] followers, [--] engagements

"$TYRA - Phase2 🚀 ➤ -0.88% +11.33% - ➤ RVOL [----] - ➤ [-----] / 17.65% - $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU"
X Link 2026-02-05T08:33Z [---] followers, [--] engagements

"$TYRA BiotechAnalyst ChrisRaymond $TYRA Layering UTUC Into Our Dabogratinib Model$TYRA Dabogratinib Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first approved indication for dabogratinib. Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first"
X Link 2026-02-05T08:46Z [---] followers, [--] engagements

"$ASPI PDRadiopharma PSMA *1 mCRPC 177Lu-PSMA-I&T Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC) $ASPI https://t.co/Anw7EPIg7l Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic"
X Link 2026-02-05T09:47Z [---] followers, [----] engagements

"$ALXO Director [---] Catalist ( ) Phase2 [--] - + - ( ASPEN-09-Breast ) HER2 Phase1 [----] - ALX2004 - $XBI $IBB $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB https://t.co/m1ID3Ym3kJ $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB"
X Link 2026-02-05T09:56Z [---] followers, [---] engagements

"$SRPT $SRPT SRP-1005 $QURE $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw"
X Link 2026-02-05T09:58Z [---] followers, [----] engagements

"$QURE 10:30 $QURE [----] tomorrow. Thats when we get data $QURE [----] tomorrow. Thats when we get data"
X Link 2026-02-06T20:22Z [---] followers, [---] engagements

"$QURE AMT-191 $QURE ( ) AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be"
X Link 2026-02-06T20:42Z [---] followers, [---] engagements

"$QURE ( ) HD FDA AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key."
X Link 2026-02-06T20:43Z [---] followers, [---] engagements

"$WVE CantorFitzgerald Webinar $WVE WV-007 [-----] - - BMI100 $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients. $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients"
X Link 2026-02-07T07:04Z [---] followers, [---] engagements

"$EIKN 200IPO $MRK 10% $XBI $IBB $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap"
X Link 2026-02-07T07:21Z [---] followers, [---] engagements

"$TYRA - Jefferies TyraBiosciences ( PT ) $32$43 : $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from $153 Buy - $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from"
X Link 2026-02-08T15:45Z [---] followers, [--] engagements

"#SPX #Stocks S&P500 CTA STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"
X Link 2026-02-08T20:36Z [---] followers, [---] engagements

"#SPX #Stocks $GS CTA [---] - S&P500 [---] STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"
X Link 2026-02-08T20:39Z [---] followers, [---] engagements

"$BFRI [---] Q4 [----] $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races"
X Link 2026-02-09T12:20Z [---] followers, [---] engagements

"@aleabitoreddit $RDDT"
X Link 2026-02-09T12:38Z [---] followers, [---] engagements

"$AXSM [--] $AXSM ADA [---] PDUFA More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk"
X Link 2026-02-09T12:51Z [---] followers, [---] engagements

"$ETON 2026-02-09 : $14.76 PDUFA : 2026-02-25 ET-600 ( ( ) ) PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600 PoA: 85%"
X Link 2026-02-09T14:27Z [---] followers, [--] engagements

"$ETON Catalist - 2026-02-25 - ET-600 - PoA85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85%"
X Link 2026-02-09T14:30Z [---] followers, [---] engagements

"$ETON [---] ( 200DMA ) Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8 Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8"
X Link 2026-02-09T14:34Z [---] followers, [--] engagements

"$ETON +3.75% EtonPharmaceuticals [---] FDA [----] https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and mid-2026 launch as first generic alternative. https://t.co/TRnDNA9ZxD https://t.co/h6ZQbBJrLH https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and"
X Link 2026-02-09T14:37Z [---] followers, [--] engagements

"$ETON $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn"
X Link 2026-02-09T14:39Z [---] followers, [--] engagements

"$ETON $KYTX $ETON 2/25 PDUFA $KYTX Phase2 BLA2026 Phase2 Catalist @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026) @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026)"
X Link 2026-02-09T14:42Z [---] followers, [---] engagements

"$BFRI - Phase3 Ameluz 85%12% sNDA [-----] Catalist $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst. $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst"
X Link 2026-02-09T14:46Z [---] followers, [---] engagements

"$TTRX - GX-03 Phase2 FDA Medline/MiMedx [----] 6.5% Phase3 [----] $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for [----]. $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for 2027"
X Link 2026-02-09T14:48Z [---] followers, [--] engagements

"$HUMA Humacyte DOD [----] $Huma #Israel #Iran #Ukraine http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in Isreal should be approved in next 60-90 days or faster. $Huma #Israel #Iran #Ukraine https://t.co/1psvbFahOa https://t.co/hwzljqLJLe http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in"
X Link 2026-02-09T15:11Z [---] followers, [---] engagements

"$HUMA $HUMA DOD 12% $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS"
X Link 2026-02-09T15:13Z [---] followers, [---] engagements

"$DUOL $HIMS 80% $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't https://t.co/PIiwzxkYA7 $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't"
X Link 2026-02-09T19:17Z [---] followers, [---] engagements

"$DUOL $DUOL @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6 @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6"
X Link 2026-02-09T19:19Z [---] followers, [---] engagements

"$DUOL @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough"
X Link 2026-02-09T19:21Z [---] followers, [---] engagements

"$SOFI GBULBorrow EVP SoFiTechnologies General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj"
X Link 2026-02-09T19:36Z [---] followers, [---] engagements

"$LTRX $QCOM $TER $LTRX $QCOM $TER $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB"
X Link 2026-02-09T19:39Z [---] followers, [--] engagements

"$CRVS $CRVS Ph1b/2 SQL 400mg QD [----] $CRVS Phase2 US/Global 400mg QD $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies. $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies"
X Link 2026-02-09T20:04Z [---] followers, [---] engagements

"$VNDA - [---] PDUFA $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG"
X Link 2026-02-09T21:09Z [---] followers, [---] engagements

"$VNDA [--] [--] $XBI $LLY $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy"
X Link 2026-02-09T21:12Z [---] followers, [---] engagements

"$ETON $VNDA [--] PDUFA $ETON $VNDA $XBI Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries. Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries"
X Link 2026-02-09T21:14Z [---] followers, [---] engagements

"$CRVS $APGE $NKTR $KYMR ( ) $NKTR + $KYMR /JAKi Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or required nave patients https://t.co/3IF66KMKGJ Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or"
X Link 2026-02-10T08:27Z [---] followers, [---] engagements

"$AARD - Phase3 HERO [--] ToplineData [--] $BIOA $IBIO $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting. $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting"
X Link 2026-02-10T13:49Z [---] followers, [---] engagements

"$AARD ARD-101 Phase3 FDA IRB $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m"
X Link 2026-02-10T13:53Z [---] followers, [--] engagements

"$EVMN - Evommune EVO301 Phase2a $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis"
X Link 2026-02-10T13:56Z [---] followers, [--] engagements

"$VNDA VandaPharmaceuticals HETLIOZ FDA https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob"
X Link 2026-02-11T13:43Z [---] followers, [---] engagements

"$VRTX $VNDA Vertex [----] Jounravx [---] $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises"
X Link 2026-02-11T13:53Z [---] followers, [---] engagements

"$VRTX JOURNAVXsuzetrigine [--] NaV1.8"
X Link 2026-02-11T13:54Z [---] followers, [--] engagements

"$ASPI [---] Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ"
X Link 2026-02-11T13:57Z [---] followers, [---] engagements

"$ASPI BNPParibasAssetManagementUK files 13G disclosing ownership of close to 1mm shares of $ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"
X Link 2026-02-11T14:00Z [---] followers, [---] engagements

"$ASPI BNPUK 13G$ASPI [---] $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"
X Link 2026-02-11T14:01Z [---] followers, [---] engagements

"$ASPI $ASPI TaronisFuels IR $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo"
X Link 2026-02-11T16:28Z [---] followers, [---] engagements

"$GELS Gelteq HealthyExtracts $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm"
X Link 2026-02-11T21:20Z [---] followers, [--] engagements

"$VNDA 📉 ⚡ 7/10 : $VNDA4 💡 VNDA10.1% 👉 #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA declining [----] 👉 https://t.co/M6U3eWkjtJ #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA"
X Link 2026-02-11T21:53Z [---] followers, [---] engagements

"$VNDA Vanda VQW-765 YE26 Phase3 Phobia Social $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf"
X Link 2026-02-12T20:29Z [---] followers, [--] engagements

"$NKTR Rezpegaldesleukin Rezpeg NektarTherapeutics T RegulatoryTcell : Treg IL-2 ( )"
X Link 2026-02-12T21:46Z [---] followers, [---] engagements

"$NKTR ( ) IL-13 Rezpeg First-in-class Treg"
X Link 2026-02-12T21:47Z [---] followers, [---] engagements

"$OGN Organon 2025Q4 📊 ❌ EPS: $0.63 : 30.00% (from $0.90) ❌ : $1.507B : 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B)"
X Link 2026-02-13T04:29Z [---] followers, [--] engagements

"$OGN [------] Nexplanon 7% $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today. $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today"
X Link 2026-02-13T04:33Z [---] followers, [--] engagements

"$ASPI $ASPI [---] BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN"
X Link 2026-02-13T13:26Z [---] followers, [----] engagements

"$OCUL $OCUL AXPAXLI AMD SOL-1 Phase3 [-----] [--] $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th"
X Link 2026-02-13T14:28Z [---] followers, [---] engagements

"$OCUL ( ) - [--] SOL-R Phase3 [---] 1Q'27 $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase 3"
X Link 2026-02-13T14:31Z [---] followers, [---] engagements

"$NUVB NuvationBio IDH1 Safusidenib Phase3 SIGMA G203 https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM"
X Link 2026-02-09T19:10Z [---] followers, [---] engagements

"$NUVB IDH1 ( Safusidenib ) Phase3 G203 $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix"
X Link 2026-02-09T19:31Z [---] followers, [---] engagements

"$VNDA Vanda Milsaperidone Phase3 YE26 $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW"
X Link 2026-02-12T20:32Z [---] followers, [---] engagements

"$KYMR $CRVS $APGE Phase2b AD ( ) Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance"
X Link 2026-02-13T21:26Z [---] followers, [---] engagements

"$KYMR $CRVS $APGE $NKTR ( ) - $KYMR KT-6211652 $CRVS #1230 - $APGE $NKTR [----] Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE"
X Link 2026-02-13T21:27Z [---] followers, [---] engagements

"$AQST - FDA NDA $AQST $SPRY CRL [--] ( ) $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within [--] $AQST - The company said that the FDA has found deficiencies in the NDA. AQST did not list any specifics. This is the advantage of having the Fast Track designation. I believe it will be worked out. Remember what happened to $SPRY even with CRL the price recovered within 4"
X Link 2026-01-09T14:34Z [---] followers, [---] engagements

"$CLPT $CLPT BBB ( ) ( ) ( ) @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk. @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably"
X Link 2026-02-08T20:20Z [---] followers, [---] engagements

"$MDGL [--] siRNA MASH [------] http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could reach US $4.4 billion https://t.co/hYvsykdfgp http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could"
X Link 2026-02-11T14:04Z [---] followers, [---] engagements

"$CRVS ITK #Soquelitinib AD 🔹 🔹 EASI-75 🔹 $NKTR $KYMR $EVMN $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing signals that you can get durative efficacy" https://t.co/6WkozViVTB $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing"
X Link 2026-02-13T21:34Z [---] followers, [---] engagements

"$QURE - FDA 150% vs 30% $QURE AMT-130 AA $CLPT $CLPT [--] $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for"
X Link 2026-02-04T16:49Z [---] followers, [---] engagements

"$QURE $QURE $CLPT $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the"
X Link 2026-02-04T16:50Z [---] followers, [----] engagements

"$CLPT ( ) 3%5-7% @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk. @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk"
X Link 2026-02-08T20:21Z [---] followers, [---] engagements

"$XBI / $ARDX $DAWN $SLNO $TMDX $HROW #ARDX #DAWN #SLNO #TMDX #HROW #XBI $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW"
X Link 2026-02-09T16:14Z [---] followers, [--] engagements

"$OCUL SOL-1Phase3 - SOL-1 [--] - SOL-1 [--] WetAMD AXPAXLI NDA ( ) $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of 631"
X Link 2026-02-13T14:30Z [---] followers, [---] engagements

"#Iran #Uranium #HEU 400HEU Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s"
X Link 2026-02-13T21:18Z [---] followers, [---] engagements

"RT @TakayamaJoe: 214807.2"
X Link 2026-02-16T04:42Z [---] followers, [---] engagements

"$RLAY CDK4/6 PIK3CAHR+/HER2- * FDA BTD * ( ) #PDUFA #FDA # # # $RLAYCDK4/6PIK3CAHR+/HER2-FDABTD $RLAYCDK4/6PIK3CAHR+/HER2-FDABTD"
X Link 2026-02-06T15:11Z [---] followers, [---] engagements

"RT @DeNebulord: $aspi could it get to $4 It's possible based on HTF support. But cash per share $2 so seems hard to believe https://t.co"
X Link 2026-02-06T21:22Z [---] followers, [--] engagements

"$HUMA $HUMA Insiders selling seeing reports Huma may have to file for bankruptcy $huma Insiders selling seeing reports Huma may have to file for bankruptcy $huma"
X Link 2025-02-28T16:53Z [---] followers, [---] engagements

"$BTC #Trump #TrumpTariffs Bitcoin 1+10% @Trading_Espada Bitcoin is experiencing significant price fluctuations of +10% per day. Despite this volatility the price remains within the same range. A major breakout is imminent. Whether is it up or down We at @Trading_Espada are ready $BTC #Trump #TrumpTariffs $ALT Bitcoin is experiencing significant price fluctuations of +10% per day. Despite this volatility the price remains within the same range. A major breakout is imminent. Whether is it up or down We at @Trading_Espada are ready $BTC #Trump #TrumpTariffs $ALT"
X Link 2025-03-05T15:04Z [---] followers, [--] engagements

"$LXRX $NVO LX9851 [--] $LXRX $NVO [--] LX9851 http://247marketnews.com $LXRX Lands up to $1B Novo Nordisk Deal for LX9851 Obesity Game-Changer DENVER Colo. Mar [--] [----] (https://t.co/BqScmIGOk0)- $LXRX just inked a blockbuster deal with $NVO handing over the keys to LX9851 a first-in-class oral non-incretin obesity drug in an exclusive http://247marketnews.com $LXRX Lands up to $1B Novo Nordisk Deal for LX9851 Obesity Game-Changer DENVER Colo. Mar [--] [----] (https://t.co/BqScmIGOk0)- $LXRX just inked a blockbuster deal with $NVO handing over the keys to LX9851 a first-in-class oral non-incretin"
X Link 2025-03-28T14:08Z [---] followers, [---] engagements

"@ni_bingbing_jie @Xg3sT57W994pQc"
X Link 2025-03-28T21:12Z [---] followers, 23.7K engagements

"$ASPI [-----] https://kemmerergazette.com/stories/kemmerer-mine-layoffs-leave-community-grappling-with-good-bad-of-energy-transition64972 $ASPI wrong date before but the next target is March [----] and has not yet been reported This article talking about the Terrapowers Natrium project https://t.co/KrPweTeP49 https://t.co/HWTHvKEH6v https://kemmerergazette.com/stories/kemmerer-mine-layoffs-leave-community-grappling-with-good-bad-of-energy-transition64972 $ASPI wrong date before but the next target is March [----] and has not yet been reported This article talking about the Terrapowers Natrium"
X Link 2025-04-10T10:56Z [---] followers, [---] engagements

"$PRSO $BULL $THRD $XAGE $HIT NASDAQ: PRSO #PROS #BULL #THRD #XAGE #HIT $PRSO mentioned in this news article last week along with $BULL $THRD $XAGE $HIT also mentioned in the article Peraso Inc. (NASDAQ: PRSO) Surges on Game-Changing Patent More Stocks Inside Link to article: https://t.co/1TLgzwwD8U $PRSO mentioned in this news article last week along with $BULL $THRD $XAGE $HIT also mentioned in the article Peraso Inc. (NASDAQ: PRSO) Surges on Game-Changing Patent More Stocks Inside Link to article: https://t.co/1TLgzwwD8U"
X Link 2025-04-23T15:52Z [---] followers, [---] engagements

"$BDRX FAP ) MUTYH"
X Link 2025-04-28T18:39Z [---] followers, [---] engagements

"$ABEO 🧬 FDA RDEB ) ZEVASKYN Catalist $ABEO ✅ Today the FDA approved ZEVASKYN the first-ever gene therapy for RDEB. 🧬 A historic moment as its the first and only approved treatment for this rare disease. But the market didnt fully price it yet eyes are now on the next catalysts: 🔹 PRV sale 🤝 Partnership / https://t.co/4QUPtjJFKc $ABEO ✅ Today the FDA approved ZEVASKYN the first-ever gene therapy for RDEB. 🧬 A historic moment as its the first and only approved treatment for this rare disease. But the market didnt fully price it yet eyes are now on the next catalysts: 🔹 PRV sale 🤝"
X Link 2025-04-29T20:31Z [---] followers, [---] engagements

"$ABEO 3VIITAL [--] $ABEO FDA Approves ZEVASKYN ✅ ZEVASKYN (prademagene zamikeracel) first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) 🧪 Based on Ph3 VIITAL study demonstrating significant wound healing & pain reduction from a single treatment with a https://t.co/E6htv1g7Lr $ABEO FDA Approves ZEVASKYN ✅ ZEVASKYN (prademagene zamikeracel) first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) 🧪 Based on Ph3 VIITAL study demonstrating significant wound healing & pain reduction from a single treatment with a https://t.co/E6htv1g7Lr"
X Link 2025-04-30T21:24Z [---] followers, [--] engagements

"$ASPI ( ) One of the three largest pension fund managers in the world. This is no accident $ASPI One of the three largest pension fund managers in the world. This is no accident $ASPI"
X Link 2025-05-02T15:11Z [---] followers, [---] engagements

"$RCKT PKP2 EU3 #Biotec #RCKT Rocket Pharmaceuticals $RCKT: enterprise value has dropped to $200M due to regulatory issues yet it could soon achieve two approvals and lucrative PRVs plus near-term PKP2 data and pivotal Danon results by early [----]. Given its Fanconi Anemia programs EU review and $300M+ peak Rocket Pharmaceuticals $RCKT: enterprise value has dropped to $200M due to regulatory issues yet it could soon achieve two approvals and lucrative PRVs plus near-term PKP2 data and pivotal Danon results by early [----]. Given its Fanconi Anemia programs EU review and $300M+ peak"
X Link 2025-05-09T21:27Z [---] followers, [---] engagements

"$LXRX III Multiple Phase III Studies for Tough Cardio/Neuro Diseases You can ask for full report in comments $LXRX $UNH $NVO $JNJ $ABBV $MRK $RHHBY $AZN $NVS $TMO $AMGN $PFE $ISRG $SNY $VRTX $SYK $ELV $REGN $BSX $BMY $HCA $GILD $CI $ZTS $CL $GSK $CVS $DSNKY $ZEAL $TAK $HUM $CNC $EW $MRNA https://t.co/ViXwsv6Xl6 Multiple Phase III Studies for Tough Cardio/Neuro Diseases You can ask for full report in comments $LXRX $UNH $NVO $JNJ $ABBV $MRK $RHHBY $AZN $NVS $TMO $AMGN $PFE $ISRG $SNY $VRTX $SYK $ELV $REGN $BSX $BMY $HCA $GILD $CI $ZTS $CL $GSK $CVS $DSNKY $ZEAL $TAK $HUM $CNC $EW $MRNA"
X Link 2025-05-15T15:21Z [---] followers, [---] engagements

"$LXRX 2b [--] $LXRX Pilavapadin Phase 2b results looking promising. Potential game-changer for neuropathic pain treatment. Watching closely for Phase [--] development. Might add to my biotech watchlist. compelling article: https://t.co/GjgtzG91Vf $LXRX Pilavapadin Phase 2b results looking promising. Potential game-changer for neuropathic pain treatment. Watching closely for Phase [--] development. Might add to my biotech watchlist. compelling article: https://t.co/GjgtzG91Vf"
X Link 2025-05-16T03:25Z [---] followers, [---] engagements

"#Gold #Bitcoin [---------] BREAKING: Gold prices extend gains to +5% since their May 15th low and near $3300/oz as markets price-in uncertainty. Gold and Bitcoin are becoming the ONLY global safe havens. https://t.co/oylJ9C5r4a BREAKING: Gold prices extend gains to +5% since their May 15th low and near $3300/oz as markets price-in uncertainty. Gold and Bitcoin are becoming the ONLY global safe havens. https://t.co/oylJ9C5r4a"
X Link 2025-05-20T20:54Z [---] followers, [---] engagements

"$ASPI TerraPower Renergen HALEU Heres the fast take on ASP Isotopes. $ASPI - Quantum Enrichment tech puts it at the center of clean-nuke chip & medical-isotope demand. TerraPower backing + Renergen bid open high-value lanes but scaling HALEU needs big capex & clear regs. https://t.co/g9T6QLG7VS Heres the fast take on ASP Isotopes. $ASPI - Quantum Enrichment tech puts it at the center of clean-nuke chip & medical-isotope demand. TerraPower backing + Renergen bid open high-value lanes but scaling HALEU needs big capex & clear regs. https://t.co/g9T6QLG7VS"
X Link 2025-06-04T15:21Z [---] followers, [---] engagements

"$IVVD Invivyd 🔹 CANOPY [--] PEMGARDA 🔹 SARS-CoV-2 COVID-19 👆 0% / $0.75 $IVVD - Invivyd 🔹Announces Publication of Landmark CANOPY Phase [--] PEMGARDA (pemivibart) Clinical Trial 🔹Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant Immune-Evasive SARS-CoV-2 Virus 👆 0% https://t.co/irbzKPZPQf $IVVD - Invivyd 🔹Announces Publication of Landmark CANOPY Phase [--] PEMGARDA (pemivibart) Clinical Trial 🔹Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against"
X Link 2025-06-30T15:46Z [---] followers, [---] engagements

"$SNYR : Core-Mark FOCUSfactor Focus + Energy #CoreMark #NationalDistribution #FunctionalBeverages #FOCUSfactor #Q3Launch $SNYR National Breakthrough: Core-Mark a Performance Food Group division and North America's largest food distributor grants national authorization for FOCUSfactor Focus + Energy beverages. The network spans 50000+ customer locations and [--] distribution centers across all [--] $SNYR National Breakthrough: Core-Mark a Performance Food Group division and North America's largest food distributor grants national authorization for FOCUSfactor Focus + Energy beverages. The network"
X Link 2025-06-30T15:55Z [---] followers, [--] engagements

"$SNYR [----------] #CoreMark #NationalDistribution #FunctionalBeverages #FOCUSfactor #Q3Launch $SNYR National Breakthrough: Core-Mark a Performance Food Group division and North America's largest food distributor grants national authorization for FOCUSfactor Focus + Energy beverages. The network spans 50000+ customer locations and [--] distribution centers across all [--] $SNYR National Breakthrough: Core-Mark a Performance Food Group division and North America's largest food distributor grants national authorization for FOCUSfactor Focus + Energy beverages. The network spans 50000+ customer"
X Link 2025-06-30T15:55Z [---] followers, [--] engagements

"$CAPR CDC DMD $CAPR is working on deliver tech with CDC spheres to deliver therapies. They are working on DMD. The infectious disease portion prevents me from going further in this environment. $CAPR is working on deliver tech with CDC spheres to deliver therapies. They are working on DMD. The infectious disease portion prevents me from going further in this environment"
X Link 2025-08-20T14:49Z [---] followers, [---] engagements

"$ARDX $ARDX 2025162024119% 📍637 📍202589 📍2025 $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're expecting a strong 2h'25. https://t.co/mtplRwxCyU $ARDX Kyowa Kirin who license the tenapanor drug from $ARDX announced a 119% increase in sales for the Jan-Jun [----] period compared to [----]. 📍In first [--] months they did [---] Bill in sales. 📍Their target for FY25 is [---] Bill. 📍That means they're"
X Link 2025-08-20T17:05Z [---] followers, [---] engagements

"$IONS / $NTLA $IONS #Anaphylaxis $NTLA [--] $ions Approved but not a perfect safety profile with #anaphylaxis apparently having been seen in addition to some platelet and liver enzyme changes. Another advantage of 1-time $ntla. $ions Approved but not a perfect safety profile with #anaphylaxis apparently having been seen in addition to some platelet and liver enzyme changes. Another advantage of 1-time $ntla"
X Link 2025-08-22T14:04Z [---] followers, [---] engagements

"TOTO (5332) rebounded significantly. - TOTO plans to increase sales in its Americas business by 40% to approximately [---] billion yen by the fiscal year ending March [----]. TOTO5332 TOTO U.S.A. [------] [----------] https://t.co/smEubVIJSc TOTO5332 TOTO U.S.A. [------] [----------] https://t.co/smEubVIJSc"
X Link 2025-08-25T18:01Z [---] followers, [---] engagements

"$ABCL $ABCL [--] [--]. + AI (Celium) COVID [--] Top [--] reasons to watch $ABCL : [--]. Faster smarter antibody discovery : Microfluidics + AI (Celium) screens millions of cells to find the right antibody. They have the ability to do it within weeks months (not years) Ex : COVID antibody identified in [--] days. https://t.co/v1FLXZwau2 Top [--] reasons to watch $ABCL : [--]. Faster smarter antibody discovery : Microfluidics + AI (Celium) screens millions of cells to find the right antibody. They have the ability to do it within weeks months (not years) Ex : COVID antibody identified in [--] days."
X Link 2025-08-26T13:49Z [---] followers, [---] engagements

"$CYTK $CYTK [--] If what I am hearing is correct $CYTK is trading up 35% in over seas markets on the great data over the weekend. That should help amplify my YTD performance tomorrow. I think we have another home run in the making. If what I am hearing is correct $CYTK is trading up 35% in over seas markets on the great data over the weekend. That should help amplify my YTD performance tomorrow. I think we have another home run in the making"
X Link 2025-09-01T15:31Z [---] followers, [---] engagements

"@miu_et496 (Grok ) Grok"
X Link 2025-09-01T16:53Z [---] followers, 26.4K engagements

"$ASPI ASP [---] [----] [---] ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is"
X Link 2025-09-02T15:14Z [---] followers, [----] engagements

"$ASPI PET [----] [----] [----] ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is"
X Link 2025-09-02T15:15Z [---] followers, [---] engagements

"$ASPI [--] Phase1C [----] 2026Phase2 ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is ASP Isotopes $ASPI just graduated to commercial stage. From R&D to delivery now a 170-person team confident enough to guide revenues. First shipments of Ytterbium-176 & Silicon-28 confirmed today unlocking tens of millions as production scales. South Africas PET Labs is"
X Link 2025-09-02T15:16Z [---] followers, [---] engagements

"$ASPI 2000/kgQLE SMR HALEU $ASPI there it is Shipment of Ytterbium is official. This is a major milestone as not only does it unlock a $20M/kg market that has an extremely constrained supply chain but it also proves that QLE works paving the path to be the only meaningful producer of HALEU for next gen $ASPI there it is Shipment of Ytterbium is official. This is a major milestone as not only does it unlock a $20M/kg market that has an extremely constrained supply chain but it also proves that QLE works paving the path to be the only meaningful producer of HALEU for next gen"
X Link 2025-09-02T15:20Z [---] followers, [---] engagements

"$XFOR $XFOR $4.23$4.50 $5 $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips. $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips"
X Link 2026-01-07T20:36Z [---] followers, [--] engagements

"$UTHR 🧬 UnitedTherapeutics MiroliverELAP Phase1 - ✅ 100% ✅ ➡ Phase2 : https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf https://ir.unither.com//media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/press-release-miroliverelap-phase-1-results.pdf"
X Link 2026-01-27T10:33Z [---] followers, [--] engagements

"$TLPH $CRMD [----] $CRMD $TLPH [----] Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full"
X Link 2026-02-03T22:53Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing